Log In
Print this Print this

PB103 (formerly PB3)

  Manage Alerts
Collapse Summary General Information
Company Pivotal BioSciences Inc.
DescriptionLEC/NHS76 fusion protein composed of a cancer-targeting antibody and CC chemokine LEC (liver-expression chemokine, CCL16)
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today